Omrix Biopharmaceuticals Ltd. Sustainability Profile
Omrix Biopharmaceuticals Ltd., a prominent player in the biopharmaceutical industry, is headquartered in Israel (IL) and operates extensively in various global markets. Founded in 2000, the company has established itself as a leader in the development and manufacturing of innovative therapeutic solutions, particularly in the fields of immunology and oncology. Omrix is renowned for its unique core products, including advanced biologics and biosimilars, which are designed to address critical medical needs. The company’s commitment to quality and innovation has positioned it favourably within the competitive landscape, earning recognition for its contributions to patient care. With a focus on research and development, Omrix continues to achieve significant milestones, solidifying its reputation as a trusted name in biopharmaceuticals.
DitchCarbon Score
How does Omrix Biopharmaceuticals Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Omrix Biopharmaceuticals Ltd.'s score of 78 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Omrix Biopharmaceuticals Ltd., headquartered in Israel (IL), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Johnson & Johnson, which influences its climate commitments and initiatives. Omrix Biopharmaceuticals inherits its climate strategies and targets from Johnson & Johnson, which has established various sustainability initiatives. These include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all at a cascade level of 1. However, specific reduction targets or achievements for Omrix Biopharmaceuticals are not detailed in the available data. As part of its corporate family, Omrix Biopharmaceuticals aligns with Johnson & Johnson's broader climate goals, although individual performance metrics are not disclosed. The company is expected to adhere to the sustainability practices and emissions reduction strategies set forth by its parent organisation, contributing to a collective effort towards reducing carbon footprints in the biopharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Omrix Biopharmaceuticals Ltd.'s Industry?
How Carbon Intensive is Omrix Biopharmaceuticals Ltd.'s Location?
Omrix Biopharmaceuticals Ltd.'s Scope 3 Categories Breakdown
Omrix Biopharmaceuticals Ltd.'s Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Omrix Biopharmaceuticals Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Omrix Biopharmaceuticals Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
